Wies R. Vallentgoed
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.
Journal: Cell reports. Medicine
Published: September 09, 2025
Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.
Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
Journal: Acta neuropathologica
Published: June 06, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
Journal: bioRxiv : the preprint server for biology
Published: April 02, 2024
Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort.
Journal: Neuro-oncology advances
Published: November 29, 2023
The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
Journal: Cancer research
Published: July 14, 2023
Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 15, 2022
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Journal: Acta neuropathologica
Published: December 30, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
Journal: Neuro-oncology advances
Published: July 10, 2020
Last Updated: 09/26/2026